Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of icotrokinra in biologic-naive active psoriatic arthritis
CTR20250028Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of icotrokinra in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Apr 2025; status: active.
02
Drugs
icotrokinra
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20250028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250028.